Skip to main content
SpringerLink
Log in

Immune checkpoint and BRAF/MEK inhibitors: risk of uveitis

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. proto-oncogene protein-b raf

  2. mitogen activated protein-kinase kinase

Reference

  • Dimitriou F, et al. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. European Journal of Cancer 144: 215-223, 26 Dec 2020. Available from: URL: http://doi.org/10.1016/j.ejca.2020.11.027

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Immune checkpoint and BRAF/MEK inhibitors: risk of uveitis. Reactions Weekly 1837, 10 (2021). https://doi.org/10.1007/s40278-021-88609-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-88609-6

Search

Navigation